Abstract
Background and aimsCertain novel biomarkers may predict atherosclerotic cardiovascular disease (ASCVD) events; however, data on their relationship to coronary atherosclerosis and its progression as measured by coronary artery calcium (CAC) scanning is lacking. We evaluated the association between novel biomarkers and presence or progression of CAC. MethodsThe EISNER study was a prospective trial of patients without known ASCVD. Data on CAC and several biomarkers (hs-CRP, LTβR, osteopontin [OPN], RAGE, TNFR1α and TROY) were available at baseline and 4-year follow-up. Biomarkers were standardized and summed for a composite score. CAC progression was defined by the square-root (CACSQRT) method and rapid (top decile) progression. Adjusted regression models created a final prediction model for baseline CAC and CAC progression. Results1207 subjects (mean age 58.4 ± 8 years, 53% male) were evaluated; 621 had a baseline CAC >0, in whom 323 progressed by CACSQRT, and 121 rapidly progressed. Baseline CAC was associated only with OPN (p = 0.03), TROY (p = 0.0058) and TNFR1α (p = 0.0039) in unadjusted analyses. In adjusted analyses, only OPN was independently related to CAC progression using CACSQRT (p = 0.04). ConclusionsOPN identifies progression of atherosclerosis in persons free of ASCVD at baseline and may be a useful predictive tool to guide ASCVD prevention management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
